# Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

> **NCT00876304** · PHASE1 · COMPLETED · sponsor: **Taisho Pharmaceutical Co., Ltd.** · enrollment: 39 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** PF-04802540
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00876304
- **Lead sponsor:** Taisho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2010-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876304, "Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00876304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*